Popular pre-market trades in the US stock market: Stak pre-market up 13.11%; Formfactor pre-market up 12.50%

Pre-market Hot Trades in US Stocks

Stak is up 13.11% in pre-market trading. There have been no significant news recently; trading is active with clear capital flows. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

FormFactor is up 12.50% in pre-market trading. Based on recent key news:

1. On July 29, FormFactor released strong third-quarter performance guidance, expecting revenue between $260 million and $280 million, exceeding the market expectation of $247.35 million. Adjusted earnings per share are expected to be between $0.77 and $0.95, higher than the expected $0.63. This optimistic performance outlook drove the stock price up 15.34% in after-hours trading. Source: Benzinga

2. On July 28, FormFactor announced a strategic partnership with Keystone Microtech to support the development of next-generation semiconductor technologies. This collaboration will enhance the production and quality of probe cards to meet the growing market demand for advanced semiconductor technologies. Source: Reuters

3. On July 29, FormFactor reported a second-quarter adjusted net income of $65 million, exceeding the market expectation of $48.5 million, which boosted the stock price. Source: Reuters The semiconductor industry is experiencing strong demand, and the market outlook is optimistic.

Top Gainers in Pre-market US Stocks

Nuwellis is up 122.75% in pre-market trading. Based on recent key news:

1. On July 27, Nuwellis announced preliminary revenue results for the second quarter of 2026, showing a year-on-year growth of 14%. This growth is mainly attributed to the commercial success of the Aquadex ultrafiltration platform, driving a significant increase in stock price.

2. On July 27, Nuwellis announced a preliminary revenue growth of 20% year-on-year for the first half of 2026. This news further boosted market confidence, leading to a substantial pre-market increase in stock price.

3. On July 27, Nuwellis is expected to release complete financial results for the second quarter of 2026 on August 13. Market expectations are positive, prompting investors to buy in, which drives the stock price up. The overall industry performance is good, with significant capital inflows.

T3 Defense is up 65.48% in pre-market trading. Based on recent key news:

1. On July 29, T3 Defense surged 81.56% during the trading session, currently reported at $23.785. This sharp increase is primarily driven by both technical and fundamental factors. The company's completed 1-for-125 reverse stock split has compressed the float to 1.12 million shares, triggering a technical short squeeze. Meanwhile, the company has made operational progress and achieved contract delivery in its Project 35 in the anti-drone technology field, and strategic investment news further boosts market confidence

2. On July 28, T3 Defense's subsidiary Industrial Techno-Logic Solutions completed the delivery of an automated composite materials production line to a major Israeli manufacturer, with a contract amount of $1.1 million. At the same time, the company holds a 60% stake in Project 35, expanding into the high-demand anti-drone technology sector. SEC Schedule 13D documents show that X S.E. Security and Defense Ltd. acquired a 16.67% stake in the company in exchange for rights to Project 35, further enhancing investor interest.

3. On July 30, T3 Defense's stock price rose by 88%, currently reported at $45.12. The stock exhibits characteristics of "low float + high trading volume," making it prone to significant volatility. Market trading is active, with clear capital flows, and caution is advised regarding volatility risks.

GlucoTrack pre-market rose by 51.68%. Based on recent key news:

1. On July 29, GlucoTrack's subsidiary Lōkahi Therapeutics announced that its LT-100 development strategy is advancing towards a single injection approach. This news boosted market confidence in the company's future development, driving a significant increase in stock price.

2. On July 29, GlucoTrack announced that clinical evaluation of LT-100 is expected to begin in the fourth quarter of 2026. This news further strengthened investors' optimistic expectations regarding the company's R&D progress, leading to a corresponding rise in stock price.

3. On July 28, GlucoTrack's capital structure indicated its use of convertible debt and private placement financing, reflecting investors' preference for structured securities and equity-linked instruments. Despite a 95.51% decline in stock price over the past 12 months, recent positive news has led to a rebound in stock price. The biotechnology sector has shown strong overall performance recently, with investors focusing on R&D progress